Sustained release polymeric gene delivery systems offer increased resistance to nuclease degradation, increased amounts of plasmid DNA (pDNA) uptake, and the possibility of control in dosing and sustained duration of pDNA administration. Furthermore, such a system lacks the inherent problems associated with viral vectors. Biodegradable and biocompatible poly(DL-lactide-co-glycolide) polymer was used to enacapsulate pDNA (alkaline phosphatase, AP, a reporter gene) in submicron size particles. Gene expression mediated by the nanoparticles (NP) was evaluated in vitro and in vivo in comparison to cationic-liposome delivery. Nano size range (600 nm) pDNA-loaded in poly(DL-lactideco-glycolide) polymer particles with high encapsulation efficiency (70%) were formulated, exhibiting sustained
Introduction
There is an increasing interest in methods for gene delivery that do not require viral vectors which are associated with immunogenicity, oncogenic properties and unknown long-term effects. 1 Such new methods represent the pharmaceutical formulation of genes that will compete against conventional pharmaceutical, biological and surgical therapies, by offering improved effectiveness, safety, compliance and modest cost. 2 Nonviral gene delivery systems, also called 'artificial viruses', although less effective, often imitate many biological functions of viral systems, but differ fundamentally from viral systems in terms of their composition, therapeutic profile, clinical risks and safety. [3] [4] [5] Such systems for gene delivery include liposomes, 6 polymeric and collagen-based matrices, [7] [8] [9] and biodegradable and nondegradable polymericbased particles. [10] [11] [12] [13] [14] The latter delivery mode offers increased resistance to nuclease degradation, the possibility of control in dosing, sustained duration of plasmid DNA (pDNA) administration, and consequently, gene action. 8, 13, 15, 16 The system also makes it possible to control the release rate kinetics, so as to time pDNA dosing, and release of pDNA of over a month. The entrapped plasmid maintained its structural and functional integrity. In vitro transfection by pDNA-NP resulted in significantly higher expression levels in comparison to naked pDNA. Furthermore, AP levels increased when the transfection time was extended, indicating sustained activity of pDNA. However, gene expression was significantly lower in comparison with standard liposomal transfection. Seven days after i.m. injections in rats, naked pDNA and pDNA-NP were found to be significantly more potent (1-2 orders of magnitude) than liposomal pDNA. Plasmid DNA-NP treatment exhibited increased AP expression after 7 and 28 days indicating sustained activity of the NP. Gene Therapy (2000) 7, 1896-1905. can be suitable in situations when long-term localized gene expression meets the aims of therapy. However, few sustained release gene delivery systems have hitherto been developed. 8, 9, 14, [16] [17] [18] Moreover, direct transfection efficiency of nanoparticles encapsulating pDNA (rather than transfection evaluation of pre-released pDNA) has not been reported.
In this work we examined the hypothesis that pDNA (human placental alkaline phosphatase, AP) encapsulated in nanoparticles (NP) fabricated from the biocompatible and biodegradable, poly(DL-lactide-co-glycolide) polymer (PLGA) can serve the goals of a controlled release gene delivery system. For a critical evaluation of such a system, the prolonged uptake by the cells and levels of expression have been examined in vitro and in vivo. Moreover, this is the first thorough study describing a sustained-release nanoparticulate delivery system of pDNA including direct transfection efficiency, structural and functional integrity, distribution of the pDNA among the NP, and disposition and cellular localization of both the NP and pDNA. The characteristics of the developed gene delivery system were evaluated in comparison with the pDNA liposomal delivery system (LIP), which is considered to be the most successful nonviral delivery system. 4, 6 Results Physicochemical characterization of PLGA-pDNA formulations The features of polymer encapsulated pDNA in NP are summarized in Table 1 . The addition of calcium to the exterior phase (formulations NP1-NP3) resulted in a high encapsulation efficiency of about 70% in comparison with only 28% in the absence of calcium (NP0). Increasing the initial concentration by two-fold, or increasing the calcium/DNA ratio by two-fold resulted in insignificant changes in the final loading of pDNA in the NP (Table 1) . pDNA in exterior and pDNA entrapped (Table 1 , row 3 and 4) do not sum up to 100 since the rest of the pDNA may have been lost in the interphase between chloroform and aqueous phase during extraction. Reduction of 33% in calcium concentration was found in the exterior phase. However, the same reduction in calcium concentration was found in both pDNA formulations and in their corresponding controls (ie particles with a similar amount of calcium but without pDNA).
Following pDNA entrapment, the z-potential of the PLGA particles decreased by 7-10 mV. The pDNAloaded PLGA particles were found to be in the nano range (Table 1 ) with a spherical shape (see Figure 1a and b). Post-labeling of pDNA-NP with the DNA fluorescence probe, Et-Br, showed a fluorescence signal in over 80% of the particles (Figure 1c ). Confocal fluorescence microscopy of cross-sectioned particles revealed pDNA distributed within the particles (figure not shown). The apparent size of the NP seems to be higher than that measured by the Coulter Counter (Table 1) , a known fluorescence-related artifact.
The release rate of entrapped pDNA was studied in comparison with a suspension of blank-NP supplemented with pDNA ( Figure 2 ). For the latter it was found that 103.0 ± 1.5% of the pDNA added was recovered after 24 h, indicating no adsorption of pDNA on the NP. The pDNA sustained release profile from the various pDNA-NP formulations (Table 1) was similar over 1 month, with a burst effect of about 50% release after 1 day.
Structural and functional integrity
Encapsulated pDNA in PLGA NP retained its structural integrity as shown following enzymatic digestion exhibiting a pattern similar to the intact pDNA ( Figure 3B ). However, the ratio between relaxed (nicked) to supercoiled conformation of encapsulated pDNA in comparison Table 1 Features of pDNA-NP preparation Gene Therapy with control pDNA increased from 30:70 to 60:40% ( Figure 3A ). pDNA either released or extracted from the various formulations (Table 1) had a similar relaxed/supercoiled pattern, and was found to be bioactive as indicated by its transfection efficiency in NIH 3T3 cells ( Table 2 ). The decreased supercoiled content seemed to cause lower expression levels but this decline was statistically insignificant.
Visualization of pDNA-NP uptake Empty nanoparticles prepared from pyrene-PLGA polymer were shown to internalize and accumulate at the cytoplasm area of the transfected NIH 3T3 cells ( Figure 4) . In order to examine the cellular uptake of pDNA-NP, encapsulated pDNA was labeled with the fluorescent probe, TOTO-1. This cell-impermeable fluorescent probe exhibits large fluorescence enhancement (1400-fold) upon binding to pDNA. Both blank-NP and naked plasmid exhibited very low fluorescence, determined as background for further analyses. In contrast, both pDNA-NP and released pDNA were detected inside the cells (Figure 5a -c). pDNA-NP were concentrated mainly in the cytoplasm (Figure 5a and c). In contrast, released pDNA (morphology resembling a nanosphere is not observed) was detected in the cytoplasm (Figure 5a ), around the nucleus (Figure 5b ), and to a lesser extent in the nucleus (Figure 5a and b). The pDNA detected inside the cell could result only from pDNA that was released intracellularly following internalization of nanoparticles containing pDNA since TOTO-1 labeled DNA is cell impermeable.
In vitro transfection
The gene expression levels in 293 cells following transfection with pDNA-NP are presented in Figure 6 . The various formulations (Table 1) had similar effects (data not shown). In comparison with naked pDNA, the delivery of pDNA by NP resulted in significantly higher expression levels (2 × 10 1 ± 0 × 10 1 and 4 × 10 2 ± 2 × 10 2 LU/mg protein, respectively). pDNA+ addition of pDNA at 1 week, resulted in luminescence levels similar to the cells-only group. In the pDNA-NP group, the AP levels were increased by 10-fold when the transfection time was extended from 48 h to 1 week, (4 × 10 ± 1 × 10 6 LU/mg protein, pDNA-LIP and pDNA-LIP + pDNA, respectively). It should be noted that addition of another positively charged compound, calcium, to the medium containing pDNA-NP did not result in enhanced transfection (data not shown). Similarly, no increase in tranfection efficiency was found following the addition of the lysosomotropic agent, chloroquine, and the osmotic swelling agent, sucrose (data not shown).
The possible deleterious effect of the presence of particles in the cell culture medium on transfection capa- bility of naked pDNA was examined by comparing the expression of cells incubated with pDNA-CaPi to those cells incubated with blank-NP + pDNA-CaPi (Table 3) . The presence of NP, either before (possible pre-transcription effect) or after (possible effect on translation) addition of naked pDNA-CaPi did not affect gene expression levels in comparison to the control group (pDNA-CaPi).
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In vivo transfection AP expression in rat tibialis muscle 3, 7 and 28 days after a single i.m. injection is shown in Figure 7 . Treatment with pDNA-NP resulted in significantly high gene expression after 3 and 7 days. However, AP levels were significantly lower after 3 days and insignificantly lower after 7 days in comparison with the pDNA group (6.1 × 10 6 ± 2.0 × 10 6 and 0.2 × 10 6 ± 0.05 × 10 6 LU/g protein, after 3 days, and 3.9 × 10 6 ± 1.2 × 10 6 and 1.3 × 10 6 ± 0.8 × 10 6 LU/g protein, after 7 days, pDNA and pDNA-NP, respectively). It should be noted that pDNA-NP mediated AP expression was increased over time (0.2 × 10 6 ± 0.05 × 10 6 and 1.3 × 10 6 ± 0.8 × 10 6 LU/g protein, 3 and 7 days, respectively). After 28 days, treatment with pDNA-NP resulted in higher gene expression than that observed in the pDNA group.
At all time-points, NP were observed in the injection site (but not in the histological sections). No adverse tissue reaction was observed. Histochemical staining of AP showed that the protein distribution in the tissue was similar for both the pDNA ( Figure 8b ) and pDNA-NP groups (Figure 8c and d).
Discussion
Much attention has been focused on biocompatible, biodegradable polymers such as PLGA, for the encapsulation of proteins and peptides, 19 and for genes. 8, 9, 14, [16] [17] [18] 20 PLGA was selected since it is a biocompatible and biodegradable polymer that is approved for in vivo applications. 19 The PLGA-NP formulations resulted in high encapsulation efficiencies of 70% (Table 1) in comparison with other reports. 18, 21, 22 In another work, utilizing a similar double emulsion technique, sonication was required for achieving high pDNA loading.
14 There are contradicting reports on the deleterious effect of sonication on DNA. 13, 16, 20, [22] [23] [24] It is suggested that our formulative approach of adding calcium ions minimized the escape of the negatively charged pDNA to the exterior phase resulting in high encapsulated pDNA yields. A similar concept was utilized recently by using the positively charged poly(l-lysine) in formulating microspheres for controlled release of complexed plasmid DNA. 21, 25 Since polylysine, especially of high MW, is associated with some toxicity, 26 the use of calcium ions instead seems advantageous. Moreover, pDNA was homogeneously distributed in the prepared NP (Figure 1c) .
Encapsulation techniques can be used to protect sensitive bioagents, such as pDNA, from degradation, 10, 11 and PLGA was reported to protect pDNA from digestion by DNase I in vitro. 22 pDNA released or extracted from the PLGA-NP formulations retained both structural and functional integrity as shown by its restriction enzymatic digestion pattern ( Figure 3B ) and its ability to transfect NIH 3T3 cells in vitro (Table 2) . However, nicking occurred and the ratio of relaxed to supercoiled conformations increased ( Figure 3A ). Supercoiled plasmid is believed to be the most efficient form and it was established that the order of transfection efficiency is supercoiled Ͼ relaxed Ͼ linear. 27 Therefore, it was important to examine the plasmid topology following encapsulation. Fabrication conditions such as sonication, lyophilization, and change of pH were reported previously to decrease the supercoiled content. 13, 16, 18, 20, 23, 24 The fabrication conditions used in our study, despite the decreased superco- Table 2 Functional integrity of pDNA encapsulated in nanoparticles (NP). Alkaline phosphatase expression levels in LU/mg protein after 48 h (1.5 g pDNA, mean ± s.e.m., n = 4) iled content, did not significantly affect the in vitro bioactivity of the encapsulated plasmid.
A sustained release profile of pDNA from the NP was exhibited (Figure 2) . Controlled release polymeric systems offer the advantage of sustained pDNA activity. 16 Some of the encapsulated pDNA was apparently accumulated in the external layers of the NP as shown by a burst of release, of about 50% release after 1 day, and the decrease of z-potential ( Figure 2 and Table 1 , respectively). Diffusion-based burst of release is typical to microencapsulated drugs in general, and pDNA in PLGA. 25 This burst of release can not be due to nonencapsulated calcium-pDNA particles since a similar calcium concentration was retained in the exterior phases of formulations with or without pDNA ( Table 1) . Adsorption of pDNA on the NP's surface is unlikely since it was found that no pDNA was adsorbed on blank NP after 24 h. It is known that various NP and microspheres/ capsules formulations are of a matrix type rather than a capsule-type. Therefore, it seems that all of the pDNA was entrapped in the NP, but some pDNA (most probably the larger plasmid in uncondensed form 15 ) was exposed on the surface of the matrix-type particle, due to the emulsification process, causing reduced zeta potential, as well as immediate release of the surface-exposed soluble plasmid. However, the remainder of the pDNA entrapped in the matrix-type polymeric particle exhibited a sustained release pattern over 1 month, in accord with the similar release patterns reported on hydrophilic proteins and drugs encapsulated in particles. 28, 29 We showed that both blank-NP and pDNA-NP per- (Figures 4 and 5,  respectively) . The pDNA-NP permeated the cells probably through endocytosis mechanism due to their small size and negatively charged surface. This is in accord with previous reports on the cell uptake mechanism of PLGA nanospheres. 28 To the best of our knowledge this is the first report describing the disposition and localization of pDNA encapsulated in PLGA-NP. Moreover, direct transfection of cells in culture by PLGA-based pDNA-NP has not been reported. A preliminary study utilizing a similar technology was published recently by one of the co-authors. 14 However, in this study sonication was used, and low transfection efficiency was demonstrated in comparison with the positive control. 14 
05). Expression was examined after 48 h and 1 week, with or without the addition of liposomes (LIP).
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Figure 8 Histochemical staining of alkaline phosphatase (AP) in tibial muscle sections of rats treated with pDNA-NP (formulation NP1). Sections shown are of saline (a), pDNA (b), and pDNA-NP (c-d). Muscles were harvested 7 days after injection, sectioned, fixed, and stained using FRV-alkaline dye mixture for AP, and counterstained with hematoxylin solution. Red spots indicate AP recombinant protein, and the nucleus is stained in blue. Magnification ×20(a-c), and ×40 (d).
The delivery of pDNA from the NP resulted in significantly higher expression levels in comparison with naked pDNA (Figure 6 ). However, the addition of lipofectamine (LIP), a well-known transfecting agent that consists of cationic and neutral lipids, 1, 4, 6 resulted in higher AP levels, in comparison with the pDNA-NP group, at both 48 h and 1 week (Figure 6 ). Lipofectamine changed the negative surface charge of the NP from negative to a positive one (data not shown) and therefore could increase cell uptake. In addition, it is reasonable to assume that some of pDNA released extracellularly was complexed with LIP facilitating cellular permeation via membrane fusion mechanism. 4, 6 It should be noted that due to the gradual release of pDNA from the nanoparticulate delivery system, lower amounts of pDNA were available during the experimental time period in comparison with nonencapsulated pDNA resulting in apparent lower expression. To this end, AP expression levels were increased after 1 week (compare 48 h to 1 week, Figure 6 ), suggesting that sustained release of pDNA was achieved. The finding that most of the pDNA was observed outside the nucleus (Figure 5) , could explain the lower gene expression mediated by the pDNA-NP in comparison to the positive control group, LIP (Figure 6 ). The neutral component of LIP (DOPE) is thought to facilitate the escape of pDNA from the endosome, 1, 4 and might enhance trafficking of pDNA to the nucleus. An attempt to facilitate the intracellularly released pDNA trafficking by the lysosomotropic agent chloroquine, or the osmotic swelling agent, sucrose, was unsuccessful. This could be due to incomplete release of the pDNA from the NP and/or timing of pDNA release with the presence of those agents.
I.M. administration of pDNA-NP in comparison with naked pDNA resulted in significantly lower expression levels of AP in the treated animals after 3 days, and insignificantly lower levels after 7 days (Figure 7 ). This could be explained by insufficient availability of released pDNA and/or lower capability of the encapsulated pDNA. The latter explanation is possible since although conformational changes do not significantly affect in vitro activity they may contribute to decreased activity in vivo. 27 Gene expression after 7 days resulting from both the naked pDNA and NP applications was found to be 1-2 orders of magnitude more potent than that observed following liposomal administration. This is in accord with previous reports that cationic liposomes, although very efficient in vitro, are found to be less potent in vivo.
6
The pDNA-NP sustained release delivery system exhibited increased transfection after 7 days in comparison to that observed after 3 days (Figure 7) . After 28 days, treatment with pDNA-NP resulted in lower expression levels than those obtained at earlier time-points, but higher than those obtained in the naked pDNA group. The overall low expression after 28 days could be ascribed to one or more of the following reasons: protein degradation, degradation of the vector components, promoter silencing or immunological effects of the pDNA used. The long-term transfection effect suggests that more pDNA-NP were taken up by the cells and/or that additional pDNA was released extracellularly from the NP at later time periods (as the NP begin to degrade). This could represent an important advantage of pDNA sustained-release formulation resulting in prolonged action of the pDNA. Further to a recent report on the sustained release gene delivery system of implantable polymeric matrices, 9 our work is the first to demonstrate this advantage in a nanoparticulate delivery system.
The comparable expression levels of pDNA-NP and naked pDNA seem to be a drawback of the delivery system. This finding is in accord with other reports on the inherited low efficiency of nonviral gene delivery systems. 1, 30, 31 However, the inherent safety issues associated with viral vectors and the sustained release pattern offer significant advantages. In addition, biodegradable polymers, such as those based on PLGA, have the potential to act as mediators of pDNA transfection targeted to phagocytic cells such as macrophages, while protecting against biological degradation by nucleases. Therefore, pDNA-NP could be particularly useful in the rapidly developing field of pDNA-based vaccines. 32 
Materials and methods
Reagents PLGA, of a lactide-glycolide ratio of 50:50, inherent viscosity of 1.13 dl/g, and MW of 123 400 was obtained from Birmingham Polymers (Birmingham, AL, USA). Polyvinyl alcohol (PVA) at average MW range of 15 000-30 000, thiazole orange, agarose, ethidium bromide, and 3-[(3-cholamidopropyl)-dimethylammonio]-1-1propanesulfonate (CHAPS) were obtained from Sigma (St Louis, MO, USA). TOTO-1 (dimeric cyanine nucleic acid stain) was obtained from Molecular Probes (Eugene, OR, USA). Lipofectamine (GibcoBRL, Gaithersburg, MD, USA), and Escort (Sigma) are similar liposome formulations of cationic (DOSPA or DOTAP) and neutral lipids (DOPE) at a ratio of 1:1 (both termed as LIP). Lipofectamine and Escort were used in the in vitro and in vivo transfection experiments, respectively. Optimal cutting temperature compound (OCT) was obtained from BDH Laboratory Supplies (Poole, UK). All other chemicals were obtained commercially at the highest analytical grade available. All buffers and solutions were filtered through 0.2 m for sterilization.
Plasmid DNA Preparation:
The human placental alkaline phosphatase (AP) gene (1.9 kbp) was cloned in pcDNA3 vector (5.4 kbp; Invitrogen, San Diego, CA, USA) forming AP/pcDNA3 reporter plasmid (7.3 kbp). The plasmid was amplified in E. coli host strain, DH5␣ extracted by the alkaline lysis technique, and purified using plasmid Giga column isolation kit (Qiagen, Hilden, Germany). Plasmid DNA concentration measurements were based on absorbancy at 260 nm, and on fluorescence assay using thiazole orange as an intercalated dye, with excitation at 500 nm and emission at 530 nm.
NP preparation and characterization
A double emulsion system and the solvent evaporation technique were used to incorporate the pDNA in PLGA. 33 Briefly, 200 l of Tris-EDTA (TE) buffer (0.1 mm Tris and 10 mm EDTA) containing 500-1000 g of pDNA (initial loading of 0.55-1.1 w/w%) were emulsified in 3% PLGA/chloroform solution (3 ml) using a homogenizer (Omni TH, Omni International, Warrenton, VA, USA) at 30 000 r.p.m. for 1.5 min. The resulting primary emulsion was added dropwise to a 2% PVA solution (in 25 ml TE), and homogenized for 4 min, forming the double emulsion. Following overnight evaporation at 4°C, the formed particles were collected by ultracentrifugation at 80 000 g (TST28 rotor, Beckman's polyallomer centrifuge tubes, 25 × 89 mm), washed three times with sterile DDW, resuspended in double distilled sterile water, and lyophilized. In some experiments, calcium chloride from a stock solution of 2.5 m was added to the PVA phase (Table 1 , row 2). Several formulations were prepared in order to study the effect of initial loading ( Table 1 , row 1) and calcium/pDNA ratio (Table 1, row 2) on encapsulation efficiency and bioactivity. The amount of pDNA entrapped in the NP (pDNA final loading) was analyzed by dissolving the NP (10 mg) in chloroform (1.5 ml), and the pDNA was extracted from the polymer solution by repetitive additions of TE buffer (×5, 0.5 ml). pDNA content and integrity were determined as described above.
Size, morphology, z-potential and pDNA distribution in the NP Laser light scattering (Coulter N4 submicron particle size analyzer, Luton, UK), scanning electron microscope and transmission electron microscope (SEM 505 and TEM CN12, respectively; Philips, Eindhoven, The Netherlands) were used to determine particle size, size distribution, and morphology. For laser light scattering, the particles were suspended in sterile DDW, the sample intensity (level of cloudiness) was between 5 × 10 4 to 1 × 10 6 counts per second, and the average number is given. The zeta potential was measured by means of a Zetamaster equipment (ZEM, Malvern Instruments, Orsay, France) using a rectangular quartz capillary cell. The particles' concentration was about 1 mg per 3 ml sterile DDW and diluted if necessary according to the instrument's cloudiness requirements.
pDNA in the NP was fluorescent-labeled after encapsulation by intercalation with ethidium bromide. Both blank and pDNA-NP (5 mg) were incubated for 3 h in ethidium bromide solution (1 g/1 ml), centrifuged, washed (×3), resuspended in sterile dd water, and examined by microscope. A confocal fluorescence laser scanning microscope was used to detect pDNA in the NP (Axiovert 135M, Ziess 410, Germany; filter set at 488/605).
In vitro release
Plasmid DNA NP (5-20 mg) were suspended in TE buffer (1 ml) and incubated at 37°C on a shaker at 100 r.p.m. (Lab Line Instruments, Melrose Park, IL, USA). At different time-points, the buffer was separated from the NP by centrifugation and analyzed for the amount and integrity of released pDNA. At each time-point, the NP were resuspended in fresh TE buffer. The release rate of entrapped pDNA was studied in comparison with a suspension of blank NP with added pDNA, PVA and calcium in amounts used in the preparation of pDNA-NP.
Cell culture studies NIH 3T3 mouse fibroblasts and 293 human endothelial cell lines were cultured in DMEM (high glucose), 10% fetal calf serum, 2 mm glutamine, and penicillin-streptomycin (100 U/ml and 0.1 mg/ml, respectively; Biological Industries, Beit Haemek, Israel). Cells were maintained at 37°C in an incubator, at a 5% CO 2 humidified atmosphere.
Structural and functional integrity
Gel electrophoresis: pDNA either released or extracted from the NP was analyzed by gel electrophoresis for purity and structural integrity before and after enzymatic digestion (1% agarose, 0.1 mg% ethidium bromide in 1 × TBE buffer, 100 V, 45 min). The marker HindIII (Sigma) and the restriction enzyme pst1/buffer H (GibcoBRL) were used for the gel analysis. pDNA released (at several time-points, from 1 day to 1 week) or extracted (the extraction method is described under NP preparation), was combined in one tube, precipitated with Et-OH, resuspended in TE buffer, and examined by gel electrophoresis. The bioactivity of released and extracted pDNA was investigated in comparison with an unencapsulated plasmid by in vitro transfection of NIH 3T3 cells, using a standard calcium phosphate (CaPi) mediated cell transfection protocol, 34 and 1.5 g pDNA. For released pDNA, a volume of the supernatant containing the same amount of pDNA was directly taken for transfection. Extracted pDNA was precipitated with Et-OH, resuspended in TE buffer, and examined for transfection. Cells were plated at a density of 1 × 10 5 cells per 35 mm well (six-well plate) and incubated for 24 h before transfection. Cells were lysed with 250 l of TMNC buffer (50 mm Tris, 100 mm NaCl, 5 mm MgCl 2 , and 4% CHAPS) 48 h after transfection, and the lysed cell supernatant was heated at 65°C for 30 min in order to inactivate endogenous AP (the recombinant AP is stable at these conditions). A specific chemiluminescence assay kit (Tropix, Bedford, MA, USA) was used to determine the recombinant AP levels by means of a luminometer (Turner Designs 2020, Sunnyvale, CA, USA). An aliquot of 20 l lysate, and 20-min incubation time were used in the assay. The average luminescence reading of the negative control group (cells only) was determined as background and was subtracted from the readings of the other experimental groups. Results were normalized to total protein content determined by BCA total protein assay (Pierce, Rockford, IL, USA), and are expressed as light units (LU) per milligram protein.
Visualization of cellular uptake
The PLGA used in this study was labeled with pyrene (Py) by esterification of the hydroxyl group of the polymer with 4-(1-pyrene)butyryl chloride as described previously, 35 forming fluorescent pyrene-PLGA. Blank-NP were prepared with the labeled polymer in order to study their uptake by cells. Cells (1 × 10 4 per chamber) were seeded on a Lab-Tek chambered cover glass system (Nalge Nunc, Naperville, IL, USA) and incubated for 24 h before transfection. The NP were suspended in the cell media (3 mg/0.4 ml) and added to the cells at NP to media volume ratio of 1/10 (300 g NP). Following incubation for 5 h, cells were carefully washed with PBS (×3), fixed with absolute methanol for 4 min, washed (×3) with PBS, and mounted with fluorescence microscopy mounting media (Sigma). Pyrene-PLGA NP localization was detected by confocal fluorescence microscopy using a UV excitation laser with appropriate filter sets.
Encapsulated pDNA was labeled with the cell impermeable DNA fluorescence probe TOTO-1 (Molecular Probes), in order to examine its cellular uptake and localization. Blank-NP (3 mg), pDNA containing NP, and a corresponding amount of naked pDNA were incubated for 0.5 h with a solution of TOTO-1 (600 l, 1 m). NP were then centrifuged, washed (×3) to remove probe access, and suspended with cell media. Transfection and fixation of cells were carried out as described above.
In vitro transfection AP expression was determined following direct transfection of 293 human endothelial cells by pDNA-NP (2 g pDNA) examining the effect of the following variables: addition of LIP (12 l of 2 mg/ml solution), lysosomotropic agent, chloroquine 36 (100 m), and an osmotic swelling agent, sucrose 37 (88 mm). Transfection was examined after 48 h and 1 week in order to evaluate the bioactivity of sustained release pDNA (bursteffect of release was observed up to 24 h). The overall expression levels in the cells + pDNA group are expected to be very low, and either to remain the same or to decrease from 48 h to 1 week (cells number increase, and results are normalized to total protein). Transfections with the liposomal formulation, LIP, served as positive control groups (named as pDNA-LIP). Since the transfection of pDNA released after 48 h could be enhanced by LIP, experimental group of cells + pDNA-NP + LIP was examined. The latter two groups were subdivided into two additional groups in which LIP, or LIP and 2 g of pDNA, were also added at 48 h. The second addition of LIP to the NP's group was carried out to see if the bioactivity of pDNA released at later time-points could be enhanced. The second addition of pDNA to the cells + pDNA and cells + pDNA-LIP groups served for comparison with the bioactivity of pDNA released at later time-points. Cells were plated in 35 mm plate in 3 ml full media (as above). Transfection experiments with the pDNA-LIP groups were performed according to the manufacturer's instructions. Briefly, 12 l of LIP and 2 g pDNA/2 l, both in 100 l of serum-free media, were combined. The 200 l solution was incubated for 20 min, 0.8 ml full media was added, and the solution was added to the cell culture plates after removing their media. The media containing LIP was replaced after 5-6 h and 1 day with fresh media. In the pDNA-NP group, 12 l of LIP was added dropwise to the NPs containing media. After 48 h, cells and media (in the NP groups, with the NP) were removed to a 10 cm dish, fresh media was added to a final volume of 10 ml, and the plates were incubated until the 1 week timepoint. In the experimental groups of second LIP addition, LIP (12 l) was added dropwise at 58 h. All groups were incubated to confluency (1 week), AP levels were determined, and the reported results were normalized to total protein content.
The possible deleterious effects of polymeric particles on transfection and expression capabilities were studied by measurement of AP (2 g of naked pDNA) expression following CaPi transfection of 293 and NIH 3T3 cell lines in the presence of blank NP. Cells were plated at a density of 1 × 10 5 cells per 35 mm plate and incubated for 24 h before transfection. Blank NP (1 mg) were suspended in the cell medium and added to the cells 6 h before or after the CaPi procedure was conducted. Cells were carefully washed free of particles (×3) in the pre-transfected group. In the control group, media was changed after 24 h. AP levels were determined 48 h after transfection.
In vivo transfection
Six-week-old Sprague-Dawley male rats (The Hebrew University of Jerusalem) were anesthetized by ether and randomly assigned. The tibial area was shaved and saline (100 l) was longitudinally injected in the muscle using a 1 ml sterile syringe fitted with a 25 G 5/8 needle (Microlance; Becton Dickinson, Fraga, Spain) as described previously. 38 pDNA (25 g pDNA/200 l saline), pDNA-LIP (containing 25 g pDNA) or pDNA-NP suspension (containing 25 g pDNA) were injected 10 min later in the same procedure. The control group received either saline or blank-NP. Three, 7 and 28 days after pDNA administration, the tibial muscle was harvested, homogenized, and incubated for 15 min with 1 ml TMNC buffer, and AP and protein concentrations in the lysate were determined as above.
Several specimens of transfected muscles (at least from two rats) were randomly excised from the control and experimental animal groups. The muscles were cut to small pieces, embedded in OCT compound and frozen at −70°C. Eight micron cross-sections were prepared using a cryostat (Cryostat CA3000, Leica Microsystems, Nu'loch, Germany). Ten randomly selected frozen sections from each group were washed with PBS, heated at 65°C for 30 min, immersed 30 s in citrate-acetone-formaldehyde fixative solution (volume ratio of 25:65:8, respectively), and incubated for 15 min with FRV-alkaline dye mixture for AP cytochemistry (Sigma). The slides were rinsed, counterstained with hematoxylin solution (Gill No. 3, Sigma), and coverslipped by aqueous mounting media.
Data analysis
Results were expressed as mean ± s.e.m. Statistical differences between groups were assessed by the Kruskal-Wallis nonparametric test, using the InStat software. When required, this test was followed by the Dunn's multiple comparisons post hoc test (*P Ͻ 0.05 was termed significant).
